United Therapeutics navigates competition with solid Q1 results, revenue growth projections, and a solid balance sheet. Learn ...

Fintel reports that on June 2, 2025, Cantor Fitzgerald initiated coverage of United Therapeutics (NasdaqGS:UTHR) with a ...

United Therapeutics Corp. (UTC) and Liquidia Technologies Inc. have been battling for close to a decade over their respective inhaled formulations ...

United Therapeutics is down 3.6% during the same time and is heading into earnings with an average analyst price target of $388.02 (compared to the current share price of $297.04).

As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including United Therapeutics (NASDAQ:UTHR) and its peers. Biotechnology ...

United Therapeutics specializes in therapies for pulmonary arterial hypertension, or high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., April 30, 2025--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the ...

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the world’s first successful transplant of a UThymoKidney™, which the company produced ...

Morningstar brands and products Company Portfolio ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the world’s first successful ...